Citius Oncology To Explore Strategic Alternatives, Engages Jefferies As Exclusive Financial Advisor

Citius Oncology, Inc. - Common Stock +4.07%
Citius Pharmaceuticals Inc +3.05%

Citius Oncology, Inc. - Common Stock

CTOR

1.28

+4.07%

Citius Pharmaceuticals Inc

CTXR

2.70

+3.05%

Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value.

The engagement of Jefferies underscores Citius Oncology's commitment to exploring all avenues for enhancing its strategic positioning and advancing its mission to improve patient outcomes in oncology. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing or other strategic transactions.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via